Vicore Pharma AB Report issue

For profit Phase 1 Phase 3
Founded: Molndal Sweden (2005)

Organization Overview

First Clinical Trial
2020
NCT04388176
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Respiratory Medicine, University College Hospital | Vicore Pharma AB

Active Ingredients

Drugs in Phase 3 Trials (1)

c21 (6 trials)

Drugs in Phase 1 Trials (3)

c106 (1 trial)

nintedanib (ofev) (1 trial)

nitroprusside (nipride) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Pulmonary Fibrosis (Phase 2)

Raynaud Disease (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4